Ken Griffin Acumen Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.22 - $3.54 $2,442 - $3,894	-1,100 Reduced 27.5%	2,900 $7,000
Q2 2024 Aug 14, 2024	BUY	$2.14 - $4.01 $4,494 - $8,421	2,100 Added 110.53%	4,000 $9,000
Q1 2024 May 15, 2024	BUY	$2.97 - $4.64 $4,158 - $6,496	1,400 Added 280.0%	1,900 $7,000
Q4 2023 Feb 14, 2024	SELL	$1.86 - $4.48 $44,454 - $107,072	-23,900 Reduced 97.95%	500 $1,000
Q3 2023 Nov 14, 2023	BUY	$4.15 - $9.72 $77,605 - $181,764	18,700 Added 328.07%	24,400 $101,000
Q2 2023 Aug 14, 2023	SELL	$3.59 - $6.59 $9,693 - $17,793	-2,700 Reduced 32.14%	5,700 $27,000
Q1 2023 May 15, 2023	SELL	$3.75 - $6.65 $168,375 - $298,585	-44,900 Reduced 84.24%	8,400 $34,000
Q4 2022 Feb 14, 2023	SELL	$4.81 - $10.17 $448,772 - $948,861	-93,300 Reduced 63.64%	53,300 $287,000
Q3 2022 Nov 14, 2022	BUY	$4.44 - $10.48 $650,904 - $1.54 Million	146,600 New	146,600 $1.47 Million

41.8M

57.7K

749K

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $89.1M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.